CAIX expression of Renca-CAIX and CT26-CAIX was approximately 3-fold lower compared with the human ccRCC cell line SKRC-52, which has been previously used in in vivo studies assessing CAIX-TRT efficacy 18 (Figure 2A, Figure S3). This evidence concerns the gene CA9 and nonpapillary renal cell carcinoma.